


# **Cell-Based Tyrosine Kinase Assay Panel**



ARNA BIOSCIENCES collaboration with



# Largest Commercially Available Panel of Tyrosine Kinase Cell-Based Assays




## Comparative cell-based analysis

- To discover direct inhibitory activity to targeted kinases
- Ready-to-run 64 Tyrosine Kinase (TK) Panel
- Time & cost saving solution for your in-house cellular assays


Survival restored by

**TK activity** 

#### Principle & Method of ACD Cell-Based Assays



Ba/F3 cells are transformed by inducting target kinase dimerization via viral vectors. Activity of the transformed kinase overrides IL3 dependency for cellular proliferation and survival - modified cells no longer require IL3 for growth.



If the kinase inhibitor (compound) specifically blocks the activity of the recombinant kinase, the modified cells undergo programmed cell death (apoptosis).

### カルナバイオサイエンス株式会社 〒650-0047 神戸市中央区港島南町1-5-5 BMA3F

TEL: 078-302-7091 (営業部直通) / FAX: 078-302-7086 E-mail: info@carnabio.com

## About ACD

Advanced Cellular Dynamics (San Diego, CA USA) is a leading provider of cell-based assay panel technologies and services to the life-sciences community. ACD develops and deploys families of cell-based screening assays, encompassing broad representations of important



target gene families. Their assays are designed to simplify high-throughput screening and profiling of chemical entities in a physiologically relevant cellular environment.



Each assay is engineered to be dependent upon maintenance of the introduced kinase activity for survival. Inhibition of this activity results in a directly proportional decrease in cell viability.

Visit our website for more information: www.carnabio.com

## www.carnabio.com


# **ACD's Cell-Based Tyrosine Kinase Assay Panel**

# Don't miss important biology using traditional assays.



# **EGFR and Lung Cancer**

Gefitinib (Iressa™) was the first EGFR tyrosine kinase inhibitor for the treatment of Non-Small Cell Lung Cancer (NSCLC).




> Only 10% of the treated population responded.



# **Mutant EGF Receptors**

Responding NSCLC patients possess a mutant EGFR.



> Two "classical" mutations L858R and **Δ746-750** 


Kinase biology can be complex.

Mutant receptors are much more responsive to Gefitinib.


Why Use Cell-based Assays?

## **Gefitinib Resistance**


Responsive patients become resistant over time.



- Resistance due to secondary "gatekeeper" mutation (T790M).
- ➤ Double mutant receptors (L858R + T790M) are much less responsive to Gefitinib.



#### **Biochemical Assay\*** K<sub>d</sub>, nM AEE788 AEE788 $35.3 \pm 0.4$ $5.3 \pm 0.3$ T790M 4.6 ± 0.1 27.6 ± 0.7 0.78 4.7 L858R L858R/T790 2.4 ± 0.1 10.9 ± 0.6 0.016 11+0 18.6 ± 0. 2.2 The ratio K /K month pro Notice that L858R/T790M affinity for Gefitinib is reduced < 5-fold relative to L858R. In tumors, the response differs by > 100-fold!



Adapted from Yun et. al. (2008). Proc. Natl. Acad. Sci. 105: 2070

Tumors bearing L858R/T790M respond poorly to Gefitinib. These differences can be missed when evaluation is performed using traditional biochemical assays, but are captured using ACD cell-based assays.

### ACD Cell-Based TK Assays Available for Screening Services

## 64 Total Kinases - Broad Coverage of the Tyrosine Kinome!

		and the second secon	
ABL (BCR-ABL)	EphA1	FMS (CSF1R)	PDGFRb
ALK	EphA3	FRK	RET
ALK [L1196M]	EphA4	HCK	RON (MST1R)
ARG (ABL2)	EphA5	HER2(ERBB2)	ROR1
AXL	EphB1	IGF1R	ROS (ROS1)
BLK	EphB2	INSR	RYK
BMX	EphB4	JAK1	SRC
BTK	FAK	JAK2	SYK
CCK4 (PTK7)	FGFR1	JAK3	TIE1
DDR2 New!	FGFR2	KDR	TIE2
EGFR	FGFR3	KIT	TRKA (NTRK1)
EGFR [ <b>A746-750</b> ]	FGFR4	LCK	TRKB (NTRK2)
EGFR [A746-750+T790M] New!	FGR	LYN	TRKC (NTRK3)
EGFR [L858R]	FLT1	MER (MERTK)	TYK2
EGFR [L858R+T790M] New!	FLT3	MET	TYRO3
EGFR [L861Q]	FLT4	PDGFRa	ZAP70

Updated : 2013/3/25

## www.carnabio.com